Your browser is no longer supported. Please, upgrade your browser.
NTLA Intellia Therapeutics, Inc. daily Stock Chart
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.28 Insider Own0.90% Shs Outstand58.75M Perf Week4.76%
Market Cap2.11B Forward P/E- EPS next Y-2.98 Insider Trans-26.24% Shs Float49.26M Perf Month40.96%
Income-120.30M PEG- EPS next Q-0.61 Inst Own87.40% Short Float26.17% Perf Quarter75.18%
Sales62.30M P/S33.92 EPS this Y-6.30% Inst Trans5.96% Short Ratio13.26 Perf Half Y104.80%
Book/sh5.61 P/B6.39 EPS next Y-29.00% ROA-30.10% Target Price35.96 Perf Year115.25%
Cash/sh6.92 P/C5.18 EPS next 5Y30.00% ROE-40.10% 52W Range9.18 - 35.54 Perf YTD144.44%
Dividend- P/FCF- EPS past 5Y-50.60% ROI- 52W High0.90% Beta1.74
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low290.63% ATR1.90
Employees270 Current Ratio7.50 Sales Q/Q109.40% Oper. Margin- RSI (14)72.83 Volatility5.71% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q2.70% Profit Margin- Rel Volume0.83 Prev Close34.81
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume971.95K Price35.86
Recom2.10 SMA2020.64% SMA5039.56% SMA20084.44% Volume804,001 Change3.02%
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Mar-08-18Initiated JMP Securities Mkt Outperform $76
Nov-01-17Reiterated Jefferies Buy $36 → $42
Jun-22-17Resumed Jefferies Buy $36
Mar-28-17Initiated Chardan Capital Markets Buy $19
Aug-05-16Upgrade Jefferies Hold → Buy
May-31-16Initiated Wedbush Outperform $38
Nov-11-20 07:30AM  
Nov-09-20 07:30AM  
Nov-06-20 05:30PM  
Nov-05-20 07:30AM  
Oct-29-20 07:30AM  
Oct-27-20 10:35AM  
Oct-19-20 07:30AM  
Oct-07-20 04:20PM  
Oct-05-20 07:30AM  
Sep-29-20 08:20AM  
Sep-28-20 08:00AM  
Sep-22-20 09:43AM  
Sep-18-20 09:31AM  
Sep-02-20 08:00AM  
Aug-11-20 11:10AM  
Aug-06-20 09:15AM  
Aug-03-20 08:00AM  
Jul-30-20 12:33PM  
Jul-25-20 11:52AM  
Jul-14-20 07:07AM  
Jul-05-20 10:52PM  
Jul-02-20 11:32AM  
Jun-10-20 11:48PM  
Jun-05-20 04:01PM  
Jun-03-20 09:56AM  
Jun-02-20 09:00PM  
Jun-01-20 04:00PM  
May-22-20 07:39AM  
May-18-20 07:12PM  
May-12-20 06:00AM  
May-11-20 07:43AM  
May-09-20 01:31PM  
May-07-20 09:15AM  
Apr-30-20 12:34PM  
Apr-28-20 04:30PM  
Apr-13-20 12:00PM  
Apr-06-20 06:26PM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Feb-27-20 08:55AM  
Feb-20-20 10:53AM  
Feb-19-20 12:31PM  
Feb-12-20 09:33AM  
Feb-10-20 07:30AM  
Feb-07-20 08:54AM  
Jan-17-20 02:09PM  
Jan-09-20 07:30AM  
Jan-06-20 11:00PM  
Dec-30-19 04:07PM  
Dec-25-19 11:30AM  
Dec-17-19 06:00AM  
Dec-14-19 09:13PM  
Dec-10-19 10:38AM  
Dec-05-19 03:49AM  
Dec-04-19 09:42AM  
Dec-03-19 01:03AM  
Dec-02-19 06:33AM  
Nov-26-19 08:00AM  
Nov-20-19 03:11PM  
Nov-19-19 10:46AM  
Nov-13-19 01:01AM  
Nov-07-19 09:44AM  
Oct-31-19 09:15AM  
Oct-30-19 08:34PM  
Oct-29-19 04:05PM  
Oct-24-19 08:00AM  
Oct-23-19 10:33AM  
Oct-16-19 08:00AM  
Oct-07-19 06:00AM  
Sep-30-19 08:00AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEONARD JOHN MPresident and CEONov 25Option Exercise6.8350,000341,500517,352Nov 25 08:02 PM
LEONARD JOHN MPresident and CEONov 25Sale36.0050,0001,800,000467,352Nov 25 08:02 PM
Rivera Jose EEVP, General CounselNov 18Option Exercise18.3084815,51847,696Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 18Sale35.0062421,84047,072Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 16Option Exercise7.4410,56278,58552,315Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 16Option Exercise14.5820,000291,600487,352Nov 18 07:56 PM
LEONARD JOHN MPresident and CEONov 16Sale34.0020,000680,000467,352Nov 18 07:56 PM
Rivera Jose EEVP, General CounselNov 16Sale34.296,029206,72846,700Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 04Option Exercise6.8350,000341,500517,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Option Exercise13.885,00069,40045,679Nov 06 04:41 PM
LEONARD JOHN MPresident and CEONov 04Sale26.0050,0001,300,000467,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Sale28.003,36494,19242,315Nov 06 04:41 PM
Rivera Jose EEVP, General CounselOct 15Option Exercise6.8310,00068,30046,294Oct 16 08:58 PM
Rivera Jose EEVP, General CounselOct 15Sale24.205,615135,88340,679Oct 16 08:58 PM
LEONARD JOHN MPresident and CEOOct 07Option Exercise6.835,00034,150472,352Oct 09 04:14 PM
LEONARD JOHN MPresident and CEOOct 07Sale21.835,000109,150467,352Oct 09 04:14 PM
Rivera Jose EEVP, General CounselSep 15Option Exercise6.8310,00068,30041,909Sep 17 04:55 PM
Rivera Jose EEVP, General CounselSep 15Sale21.045,615118,14036,294Sep 17 04:55 PM
LEONARD JOHN M.President and CEOSep 01Option Exercise6.835,00034,150472,352Sep 03 04:15 PM
LEONARD JOHN M.President and CEOSep 01Sale21.835,000109,150467,352Sep 03 04:15 PM
Rivera Jose EEVP, General CounselAug 18Option Exercise6.8310,00068,30037,524Aug 20 04:13 PM
Rivera Jose EEVP, General CounselAug 18Sale21.005,615117,91531,909Aug 20 04:13 PM
LEONARD JOHN M.President and CEOAug 06Option Exercise6.835,00034,150472,352Aug 07 07:29 PM
LEONARD JOHN M.President and CEOAug 06Sale21.835,000109,150467,352Aug 07 07:29 PM
Rivera Jose EEVP, General CounselJul 15Option Exercise6.8310,00068,30033,139Jul 17 04:18 PM
Rivera Jose EEVP, General CounselJul 15Sale22.705,615127,46127,524Jul 17 04:18 PM
LEONARD JOHN M.President and CEOJul 01Option Exercise6.835,00034,150472,352Jul 02 04:10 PM
LEONARD JOHN M.President and CEOJul 01Sale21.835,000109,150467,352Jul 02 04:10 PM
Rivera Jose EEVP, General CounselJun 16Option Exercise6.8310,00068,30027,897Jun 18 05:00 PM
Rivera Jose EEVP, General CounselJun 16Sale21.005,615117,91522,282Jun 18 05:00 PM
LEONARD JOHN M.President and CEOJun 03Option Exercise6.835,00034,150472,352Jun 05 05:18 PM
LEONARD JOHN M.President and CEOJun 03Sale21.835,000109,150467,352Jun 05 05:18 PM
Rivera Jose EEVP, General CounselMay 26Option Exercise6.8310,00068,300285,722May 28 05:23 PM
Rivera Jose EEVP, General CounselMay 26Sale21.215,615119,094280,107May 28 05:23 PM
IQV IQVIA Holdings Inc. daily Stock Chart
IQVIA Holdings Inc.
IndexS&P 500 P/E189.16 EPS (ttm)0.90 Insider Own0.40% Shs Outstand191.30M Perf Week0.47%
Market Cap32.53B Forward P/E21.63 EPS next Y7.85 Insider Trans-81.59% Shs Float189.65M Perf Month6.74%
Income176.00M PEG14.08 EPS next Q2.01 Inst Own91.80% Short Float1.00% Perf Quarter7.17%
Sales10.96B P/S2.97 EPS this Y-11.10% Inst Trans-0.53% Short Ratio1.91 Perf Half Y13.61%
Book/sh30.56 P/B5.56 EPS next Y24.15% ROA0.80% Target Price198.89 Perf Year14.81%
Cash/sh8.06 P/C21.08 EPS next 5Y13.44% ROE3.10% 52W Range81.79 - 180.77 Perf YTD9.94%
Dividend- P/FCF26.77 EPS past 5Y-18.80% ROI3.60% 52W High-6.03% Beta1.42
Dividend %- Quick Ratio1.10 Sales past 5Y15.20% Gross Margin34.00% 52W Low107.69% ATR4.69
Employees67000 Current Ratio1.10 Sales Q/Q0.60% Oper. Margin5.40% RSI (14)55.07 Volatility1.61% 2.69%
OptionableYes Debt/Eq2.13 EPS Q/Q81.00% Profit Margin1.60% Rel Volume0.82 Prev Close172.00
ShortableYes LT Debt/Eq2.11 EarningsOct 20 BMO Payout0.00% Avg Volume992.69K Price169.87
Recom1.80 SMA201.72% SMA503.99% SMA20015.34% Volume817,074 Change-1.24%
Jul-07-20Initiated Stephens Equal-Weight $150
Mar-02-20Initiated Deutsche Bank Buy $190
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Dec-13-19Upgrade CFRA Sell → Hold
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Jun-21-19Upgrade Mizuho Neutral → Buy $150 → $175
May-28-19Initiated SVB Leerink Outperform
Jan-18-19Upgrade Jefferies Hold → Buy
Oct-09-18Initiated UBS Buy
Oct-02-18Reiterated Robert W. Baird Outperform $143 → $146
Jul-25-18Upgrade BofA/Merrill Neutral → Buy
Jul-25-18Reiterated Stifel Buy $128 → $150
Jul-03-18Upgrade Raymond James Outperform → Strong Buy
Apr-13-18Upgrade Goldman Neutral → Buy
Mar-07-18Upgrade SunTrust Hold → Buy
Jan-19-18Initiated Evercore ISI Outperform $112
Nov-19-20 11:30AM  
Nov-10-20 09:43AM  
Nov-05-20 09:35AM  
Nov-02-20 08:00AM  
Oct-23-20 09:35AM  
Oct-20-20 03:00PM  
Oct-19-20 10:14AM  
Oct-15-20 10:00AM  
Oct-13-20 12:30PM  
Oct-12-20 08:00AM  
Oct-07-20 04:15PM  
Oct-06-20 08:00AM  
Sep-23-20 09:46AM  
Sep-14-20 08:10AM  
Aug-31-20 01:45PM  
Aug-26-20 02:59PM  
Aug-21-20 11:30AM  
Aug-08-20 03:04PM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-31-20 11:09AM  
Jul-30-20 11:40AM  
Jul-29-20 08:00AM  
Jul-25-20 10:39AM  
Jul-23-20 08:00AM  
Jul-22-20 01:00PM  
Jul-21-20 06:12PM  
Jul-20-20 08:01AM  
Jul-17-20 11:27AM  
Jul-15-20 12:31PM  
Jul-14-20 11:07AM  
Jul-08-20 04:15PM  
Jul-02-20 08:00AM  
Jun-23-20 06:14PM  
Jun-09-20 09:24AM  
Jun-03-20 08:00AM  
Jun-02-20 10:58AM  
Jun-01-20 10:07AM  
May-28-20 01:18PM  
May-27-20 07:14PM  
May-26-20 03:54PM  
May-21-20 08:00AM  
May-20-20 08:00AM  
May-11-20 10:08AM  
May-07-20 11:52AM  
May-01-20 08:36AM  
Apr-29-20 09:20AM  
Apr-28-20 06:01PM  
Apr-27-20 09:43AM  
Apr-24-20 12:28PM  
Apr-23-20 05:49AM  
Apr-22-20 03:04PM  
Apr-07-20 09:28AM  
Apr-06-20 07:00PM  
Apr-03-20 03:00PM  
Apr-02-20 08:29PM  
Mar-26-20 01:15PM  
Mar-24-20 08:00AM  
Mar-13-20 11:30AM  
Mar-12-20 12:41PM  
Mar-09-20 03:34PM  
Mar-07-20 10:31AM  
Feb-24-20 02:59PM  
Feb-20-20 08:49AM  
Feb-19-20 06:56AM  
Feb-17-20 06:31PM  
Feb-13-20 04:41PM  
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rittenmeyer Ronald ADirectorNov 24Sale172.969,5901,658,68611,894Nov 25 05:03 PM
Rittenmeyer Ronald ADirectorNov 16Sale174.3540,7927,112,08521,484Nov 18 05:03 PM
BOUSBIB ARISee RemarksOct 12Sale170.0069,12011,750,400652,035Oct 14 05:05 PM
BOUSBIB ARISee RemarksSep 15Sale164.3646,0807,573,709652,035Sep 17 05:06 PM
BOUSBIB ARISee RemarksAug 14Sale161.6669,12011,173,939652,035Aug 18 05:03 PM
STAUB W RICHARDSee RemarksAug 07Option Exercise87.2033,8902,955,12732,877Aug 11 05:02 PM
STAUB W RICHARDSee RemarksAug 07Sale160.3220,3673,265,33212,470Aug 11 05:02 PM
Bruehlman Ronald ESee RemarksAug 04Buy159.9410,0001,599,40026,751Aug 05 05:02 PM
TPG Group Holdings (SBS) AdvisFormer DirectorJul 28Sale159.122,919,051464,479,3950Jul 29 04:42 PM
BOUSBIB ARISee RemarksJul 22Sale160.0046,0807,372,800652,035Jul 24 05:09 PM
BOUSBIB ARISee RemarksJun 02Sale150.11164,87724,749,686652,035Jun 04 05:35 PM
BOUSBIB ARISee RemarksJun 01Sale150.0019,4432,916,450652,035Jun 03 05:35 PM
EVANISKO MICHAEL JDirectorMar 24Option Exercise21.206,600139,92011,850Mar 26 05:00 PM
Knightly Kevin CSee RemarksFeb 21Sale163.432,191358,0750Feb 25 05:02 PM
Knightly Kevin CSee RemarksFeb 19Sale165.095,688939,0322,191Feb 20 05:03 PM
STAUB W RICHARDSee RemarksFeb 18Option Exercise78.2118,2241,425,29935,953Feb 20 05:05 PM
STAUB W RICHARDSee RemarksFeb 18Sale163.7714,5502,382,85421,403Feb 20 05:05 PM
TPG Group Holdings (SBS) AdvisDirectorFeb 13Sale164.302,996,172492,271,0602,919,051Feb 18 07:00 PM
CONNAUGHTON JOHNDirectorFeb 13Sale164.30703,828115,638,940685,712Feb 18 04:29 PM
EVANISKO MICHAEL JDirectorJan 31Option Exercise23.706,250148,12511,500Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 31Sale155.196,250969,9385,250Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 24Option Exercise20.316,250126,92511,500Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 24Sale159.076,250994,1885,250Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Option Exercise18.406,250115,00011,500Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Sale160.766,2501,004,7505,250Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 10Option Exercise18.406,250115,00011,500Jan 14 04:56 PM
EVANISKO MICHAEL JDirectorJan 10Sale160.086,2501,000,5005,250Jan 14 04:56 PM
MCDONNELL MICHAEL REVP and CFOJan 02Sale155.0712,0001,860,84014,366Jan 06 05:05 PM
LEONARD JOHN M.DirectorDec 20Option Exercise64.7720,2001,308,25428,452Dec 26 04:33 PM
LEONARD JOHN M.DirectorDec 20Sale153.0020,2003,090,6008,252Dec 26 04:33 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.